Eden Research plc Voting Rights, Warrants and Options Outstanding (9018Y)
09 March 2017 - 1:40AM
UK Regulatory
TIDMEDEN
RNS Number : 9018Y
Eden Research plc
08 March 2017
8 March 2017
Eden Research Plc
("Eden" or "Company")
Total Voting Rights and Warrants and Options Outstanding
Eden Research plc (AIM: EDEN), the AIM-listed company that
provides breakthrough natural bio-control products and
microencapsulation technologies to the global agrochemicals, animal
health and consumer products industries, is today confirming its
current total voting rights and number of options and warrants
outstanding:
The Company's total issued and voting share capital comprises
184,654,119 ordinary shares of 1 pence each ("Ordinary Shares"). No
shares were held in treasury at the date of this announcement. The
total number of current voting rights in the Company is therefore
184,654,119.
The above figure (184,654,119 Ordinary Shares) is the figure
which may be used by shareholders as the denominator for the
calculation by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company.
The Company also confirms that the current number of outstanding
warrants over Ordinary Shares ("Warrants") is currently 5,497,867,
which is unchanged from the number of Warrants in issue announced
by the Company on 27 September 2016. This number includes 2,000,000
Warrants with an exercise price of 11 pence which were issued to
Oxford Capital Limited. These Warrants were issued in December 2014
in connection with the 20,865,382 new Ordinary Shares issued, as
announced by the Company on 28 November 2014, for settlement of all
outstanding debt.
In addition, the Company confirms that the current number of
outstanding options over Ordinary Shares is currently
5,025,000.
Eden Research plc www.edenresearch.com
Sean Smith, Chief Executive Tel: 01285 359 555
Officer
Alex Abrey, Chief Financial
Officer
Shore Capital and Corporate www.shorecap.com
Limited
Stephane Auton/Patrick Tel: 020 7408 4090
Castle
Walbrook PR Ltd Tel: 020 7933 8780 or eden@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
Notes:
Eden Research is a technology development and commercialisation
company with intellectual property and expertise in encapsulation,
terpenes and environmentally friendly technologies to provide
naturally occurring solutions for the global agrochemicals, animal
health, and consumer product industries.
Eden's encapsulation technology harnesses the biocidal efficacy
of naturally occurring chemicals produced by plants (terpenes) and
can also be used with both natural and synthetic compounds to
enhance their performance and ease-of-use. The technology uses
yeast cells that are a by-product of numerous commercial production
processes to deliver a slow release of natural compounds for
agricultural and non-agricultural uses. Terpenes are already widely
used in the food flavouring, cosmetics and pharmaceutical
industries.
Historically, terpenes have had limited commercial use in the
agrochemical sector due to their volatility, phytotoxicity and poor
solubility. Eden's platform encapsulation technology provides a
unique, environmentally friendly solution to these problems and
enables terpenes to be used as effective, low-risk
agrochemicals.
With leading consultants in their respective fields, the Company
is developing these technologies through innovative research and a
series of commercial production, marketing and distribution
partnerships.
The Company has a number of patents and a pipeline of products
at differing stages of development targeting specific areas of the
global agrochemicals industry. To date, the Company has invested in
the region of GBP12m in developing and protecting its intellectual
property and seeking regulatory approval for products that rely
upon the Company's technologies. Revenues earned by the Company
have been modest whilst the Company has concentrated on securing
patent protection for its intellectual property, gaining regulatory
approvals, identifying suitable industrial partners, and entering
into commercial agreements.
In May 2013, the three actives that comprise Eden's first
commercial product, 3AEY, were approved as new ingredients for use
in plant protection products. This represents a major milestone in
the commercialisation of Eden's technology and is a significant
accomplishment for any company. To illustrate this point, one
should note that in all of 2013, Eden's approvals represented 3 of
only 10 new active ingredients approved by the EC.
3AEY has been authorised for sale in Kenya, Malta, Greece,
Bulgaria, Spain, Italy and France.
Eden was admitted to trading on AIM on 11 May 2012 and trades
under the symbol EDEN.
For more information about Eden, please visit:
www.edenresearch.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLLFVSVTITIID
(END) Dow Jones Newswires
March 08, 2017 09:40 ET (14:40 GMT)
Eden Research (LSE:EDEN)
Historical Stock Chart
From Apr 2024 to May 2024
Eden Research (LSE:EDEN)
Historical Stock Chart
From May 2023 to May 2024